Literature DB >> 17379452

Predictors and patterns of recurrence after definitive chemoradiation for anal cancer.

Prajnan Das1, Sumita Bhatia, Cathy Eng, Jaffer A Ajani, John M Skibber, Miguel A Rodriguez-Bigas, George J Chang, Priya Bhosale, Marc E Delclos, Sunil Krishnan, Nora A Janjan, Christopher H Crane.   

Abstract

PURPOSE: To evaluate patterns of locoregional failure, and predictors of recurrence and survival in patients treated with chemoradiation for anal cancer. METHODS AND MATERIALS: Between September 1992 and August 2004, 167 patients with nonmetastatic squamous cell anal carcinoma were treated with definitive chemoradiation. The median dose of radiotherapy was 5500 cGy. Concurrent chemotherapy was given with 5-fluorouracil and cisplatin in 117 patients, 5-fluorouracil and mitomycin C in 24 patients, and other regimens in 26 patients.
RESULTS: The estimated 3-year rates of locoregional control, distant control, disease-free survival, and overall survival were 81%, 88%, 67%, and 84%, respectively. Multivariate analysis showed that higher T stage and N stage independently predicted for a higher rate of locoregional failure; higher N stage and basaloid subtype independently predicted for a higher rate of distant metastasis; and higher N stage and positive human immunodeficiency virus status independently predicted for a lower rate of overall survival. Among the patients who had locoregional failure, 18 (75%) had failure involving the anus or rectum, 5 (21%) had other pelvic recurrences, and 1 (4%) had inguinal recurrence. The 5 pelvic recurrences all occurred in patients with the superior border of the radiotherapy field at the bottom of the sacroiliac joint.
CONCLUSIONS: Trials of more aggressive and innovative locoregional and systemic therapies are warranted in high-risk patients, based on their T and N stages. The majority of locoregional failures involve the anus and rectum, whereas inguinal recurrences occur rarely. Placing the superior border of the radiotherapy field at L5/S1 could potentially reduce pelvic recurrences.

Entities:  

Mesh:

Year:  2007        PMID: 17379452     DOI: 10.1016/j.ijrobp.2006.12.052

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  45 in total

1.  Neoplasms of anal canal and perianal skin.

Authors:  Daniel Leonard; David Beddy; Eric J Dozois
Journal:  Clin Colon Rectal Surg       Date:  2011-03

2.  [Curative radiotherapy in patients with anal cancer: clinical outcomes and prognostic factors in a single-institution experience].

Authors:  M F Osti; L Agolli; C Scaringi; S Bracci; G Minniti; R Maurizi Enrici
Journal:  Radiol Med       Date:  2012-11-26       Impact factor: 3.469

Review 3.  Anal cancer treatment: current status and future perspectives.

Authors:  Marwan Ghosn; Hampig Raphael Kourie; Pamela Abdayem; Joelle Antoun; Dolly Nasr
Journal:  World J Gastroenterol       Date:  2015-02-28       Impact factor: 5.742

4.  Genital marginal failures after intensity-modulated radiation therapy (IMRT) in squamous cell anal cancer: no higher risk with IMRT when compared to 3DCRT.

Authors:  V Dell'Acqua; J Kobiela; F Kraja; M C Leonardi; A Surgo; M A Zerella; S Arculeo; C Fodor; R Ricotti; M G Zampino; S Ravenda; G Spinoglio; R Biffi; A Bazani; R Luraschi; S Vigorito; P Spychalski; R Orecchia; R Glynne-Jones; B A Jereczek-Fossa
Journal:  Med Oncol       Date:  2018-03-28       Impact factor: 3.064

5.  Comprehensive Genomic Profiling of Metastatic Squamous Cell Carcinoma of the Anal Canal.

Authors:  Van Morris; Xiayu Rao; Curtis Pickering; Wai Chin Foo; Asif Rashid; Karina Eterovic; Taebeom Kim; Ken Chen; Jing Wang; Kenna Shaw; Cathy Eng
Journal:  Mol Cancer Res       Date:  2017-08-07       Impact factor: 5.852

6.  The treatment of squamous anal carcinoma: guidelines of the Italian Society of Colo-Rectal Surgery.

Authors:  I Giani; M Mistrangelo; C Fucini
Journal:  Tech Coloproctol       Date:  2012-11-10       Impact factor: 3.781

7.  Clinicopathologic Features Associated With Human Papillomavirus/p16 in Patients With Metastatic Squamous Cell Carcinoma of the Anal Canal.

Authors:  Van K Morris; Asif Rashid; Miguel Rodriguez-Bigas; Prajnan Das; George Chang; Aki Ohinata; Jane Rogers; Christopher Crane; Robert A Wolff; Cathy Eng
Journal:  Oncologist       Date:  2015-09-17

8.  Saudi Oncology Society clinical management guideline series. Anal canal cancer 2014.

Authors:  Shouki N Bazarbashi; Ali M Alzahrani; Mohammed M Rahal; Ahmed S Al-Shehri; Ali H Aljubran; Nasser A Alsanea; Omar A Al-Obeed; Magdy S Kandil; Jamal E Zekri; Ashwaq A Al Olayan; Abdullah A Alsharm; Khaled S Balaraj
Journal:  Saudi Med J       Date:  2014-12       Impact factor: 1.484

9.  Chemo-radiation with or without mandatory split in anal carcinoma: experiences of two institutions and review of the literature.

Authors:  Christoph Oehler; Sawyna Provencher; David Donath; Jean-Paul Bahary; Urs M Lütolf; I Frank Ciernik
Journal:  Radiat Oncol       Date:  2010-05-13       Impact factor: 3.481

Review 10.  Anal cancer: are we making progress?

Authors:  Ajay Aggarwal; Simon Duke; Rob Glynne-Jones
Journal:  Curr Oncol Rep       Date:  2013-04       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.